TR201900350T4 - Kandesartan sileksetil ve amlodipin içeren bir farmasötik bileşim. - Google Patents

Kandesartan sileksetil ve amlodipin içeren bir farmasötik bileşim. Download PDF

Info

Publication number
TR201900350T4
TR201900350T4 TR2019/00350T TR201900350T TR201900350T4 TR 201900350 T4 TR201900350 T4 TR 201900350T4 TR 2019/00350 T TR2019/00350 T TR 2019/00350T TR 201900350 T TR201900350 T TR 201900350T TR 201900350 T4 TR201900350 T4 TR 201900350T4
Authority
TR
Turkey
Prior art keywords
candesartan cilexetil
composition
pharmaceutical composition
amlodipine
composition containing
Prior art date
Application number
TR2019/00350T
Other languages
English (en)
Inventor
Cieplucha Agnieszka
Original Assignee
Adamed Pharma S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030379&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201900350(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adamed Pharma S A filed Critical Adamed Pharma S A
Publication of TR201900350T4 publication Critical patent/TR201900350T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Kandesartan sileksetil ve amiodipin veya bunun farmasötik olarak kabul edilebilir tuzunu içeren bir kombinasyonlu farmasötik bileşim, bu tür bir bileşimin ve bu tür bir bileşimi içeren birim dozaj formunun hazırlanmasına yönelik bir prosestir. Bileşim, kandesartan sileksetil ila polietilen glikol ağırlık oranının 5:1 ila 2:1 aralığında olduğu, kandesartan sileksetil, polietilen glikol ve diğer eksipiyanları içeren bir granülattan ve amiodipin veya bunun farmasötik olarak kabul edilebilir bir tuzunu ve eksipiyanları içeren toz karışımın ekstragranüler fazından oluşur. Bileşim, ıslak granülasyon yoluyla hazırlanan granülat ile ekstragranüler fazın karıştırılması yoluyla hazırlanır.
TR2019/00350T 2012-12-21 2013-12-19 Kandesartan sileksetil ve amlodipin içeren bir farmasötik bileşim. TR201900350T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL402191A PL236001B1 (pl) 2012-12-21 2012-12-21 Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję

Publications (1)

Publication Number Publication Date
TR201900350T4 true TR201900350T4 (tr) 2019-02-21

Family

ID=50030379

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/00350T TR201900350T4 (tr) 2012-12-21 2013-12-19 Kandesartan sileksetil ve amlodipin içeren bir farmasötik bileşim.

Country Status (19)

Country Link
EP (1) EP2934488B1 (tr)
AU (1) AU2013365715B2 (tr)
BR (1) BR112015014875A2 (tr)
EA (1) EA030704B1 (tr)
ES (1) ES2706067T3 (tr)
HK (1) HK1213808A1 (tr)
HR (1) HRP20190049T1 (tr)
HU (1) HUE042194T2 (tr)
MX (1) MX2015008032A (tr)
MY (1) MY185947A (tr)
PH (1) PH12015501301B1 (tr)
PL (2) PL236001B1 (tr)
PT (1) PT2934488T (tr)
RS (1) RS58214B1 (tr)
SG (1) SG11201504473XA (tr)
TR (1) TR201900350T4 (tr)
UA (1) UA115257C2 (tr)
WO (1) WO2014097209A1 (tr)
ZA (1) ZA201505192B (tr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3236950B1 (en) * 2014-12-24 2022-11-23 KRKA, d.d., Novo mesto Pharmaceutical composition comprising candesartan or pharmaceutically acceptable salts or esters thereof and amlodipine or pharmaceutically acceptable salts thereof
CN104721159A (zh) * 2015-03-24 2015-06-24 浙江康乐药业股份有限公司 一种苯磺酸氨氯地平片及其制备方法
KR101710441B1 (ko) * 2015-12-28 2017-02-28 신풍제약주식회사 안정성 및 용출성이 향상된 정제
EP3219309A1 (en) * 2016-03-17 2017-09-20 K.H.S. Pharma Holding GmbH Fixed dosed pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension
US10350171B2 (en) * 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
EP4374855A1 (en) * 2022-11-22 2024-05-29 KRKA, D.D., Novo Mesto Pharmaceutical dosage form of candesartan and indapamide

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161312C (da) 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
TW284688B (tr) 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
PL189666B1 (pl) 1998-04-09 2005-09-30 Adamed Sp Z Oo Sposób otrzymywania benzenosulfonianu amlodypiny
HU226642B1 (en) 2001-12-17 2009-05-28 Egis Gyogyszergyar Nyilvanosan Amlodipine bezylate tablets having extended stability and process for producing the same
WO2004075825A2 (en) 2003-02-28 2004-09-10 Ranbaxy Laboratories Limited Dosage forms of amlodipine and processes for their preparation
WO2008065097A2 (en) 2006-11-28 2008-06-05 Laboratorios Liconsa, S.A. Stabilized solid pharmaceutical composition of candesartan cilexetil
JP5139515B2 (ja) 2007-04-25 2013-02-06 テバ ファーマシューティカル インダストリーズ リミティド 医薬賦形剤複合体
EP2050440A1 (en) 2007-10-18 2009-04-22 Krka Stable solid pharmaceutical composition comprising candesartan or pharmaceutically acceptable forms thereof
EP2106789A1 (en) * 2008-03-31 2009-10-07 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising candesartan
DK2165702T3 (da) 2008-09-17 2012-03-05 Helm Ag Stabile og let opløselige sammensætninger af candesartancilexetil fremstillet ved vådgranulering
NZ596395A (en) 2009-04-30 2013-06-28 Takeda Pharmaceutical Stable solid benzimidazole derivative preparation having optimized dissolution property
CN101966181A (zh) * 2010-07-08 2011-02-09 王丽燕 包含坎地沙坦和氨氯地平的口服固体制剂及其新应用
CN102743381B (zh) * 2011-04-22 2014-08-27 重庆市力扬医药开发有限公司 一种稳定的坎地沙坦酯氨氯地平药物组合物及其制备方法
CN102764258B (zh) 2011-10-21 2013-09-25 四川百利药业有限责任公司 一种坎地沙坦酯氨氯地平复方片的制备方法
CN102670603B (zh) * 2012-04-29 2017-10-31 浙江华海药业股份有限公司 含有坎地沙坦酯和苯磺酸氨氯地平的口服片剂及其制备方法
CN102688236B (zh) * 2012-06-06 2014-03-26 石药集团中诺药业（石家庄）有限公司 一种坎地沙坦酯氨氯地平片剂组合物及其制备方法

Also Published As

Publication number Publication date
HUE042194T2 (hu) 2019-06-28
RS58214B1 (sr) 2019-03-29
ES2706067T3 (es) 2019-03-27
AU2013365715B2 (en) 2017-10-05
PH12015501301A1 (en) 2015-08-24
MY185947A (en) 2021-06-14
HK1213808A1 (zh) 2016-07-15
BR112015014875A2 (pt) 2017-07-11
UA115257C2 (uk) 2017-10-10
EA201591097A1 (ru) 2015-10-30
PL236001B1 (pl) 2020-11-30
EP2934488A1 (en) 2015-10-28
PH12015501301B1 (en) 2015-08-24
PT2934488T (pt) 2019-01-29
HRP20190049T1 (hr) 2019-02-22
PL402191A1 (pl) 2014-06-23
AU2013365715A1 (en) 2015-06-18
SG11201504473XA (en) 2015-07-30
EP2934488B1 (en) 2018-10-17
ZA201505192B (en) 2016-07-27
WO2014097209A1 (en) 2014-06-26
PL2934488T3 (pl) 2019-04-30
EA030704B1 (ru) 2018-09-28
MX2015008032A (es) 2015-10-30

Similar Documents

Publication Publication Date Title
TR201900350T4 (tr) Kandesartan sileksetil ve amlodipin içeren bir farmasötik bileşim.
MY169986A (en) Benzimidazole-proline derivatives
NZ602442A (en) A fast dissolving pharmaceutical composition
IN2014MN01919A (tr)
EA201690679A1 (ru) Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан
EA201270087A1 (ru) Твердые фармацевтические композиции с фиксированной дозой, содержащие ирбесартан и амлодипин, их получение и их терапевтическое применение
SI2729130T1 (en) Combined formulations of darunavir
MX340188B (es) Elaboracion de granulos sin activos y tabletas que comprenden los mismos.
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
TR201009397A2 (tr) Rosuvastatin içeren farmasötik bileşimler.
HRP20180316T1 (hr) Izolirani čvrsti oblik anamorelin monohidroklorida s niskim molarnim odnosom klorida: anamolerina i niskim sadržajem rezidualnog organskog otapala
EA201401309A1 (ru) Фармацевтическая композиция для ингаляции, содержащая аклидиний, и её применение
BR112015012111A8 (pt) formulações de mistura de pó direta, soluções orais, e usos de um fármaco para preparação das mesmas.
JP2014527506A5 (tr)
TN2012000363A1 (en) Solid pharmaceutical formulations of ramipril and amlodipine besylate, and their preparation
EP2497464A3 (en) Pharmaceutical composition of imatinibe methanesulphonate and a process for its manufacture
EA033291B1 (ru) Единица дозирования, содержащая рамиприл и бисопролола гемифумарат, способ ее получения и способ лечения гипертензии
EA201291189A1 (ru) Фармацевтическая композиция, содержащая солифенацин, и способ его получения
DOP2015000040A (es) Formulación de comprimidos compuestos de dos fases que comprende atorvastatina, irbesartan y carbonato de magnesio
WO2011126327A3 (en) Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof
HRP20171930T1 (hr) Analozi diazonamida
RS53359B (en) COMPOSITION OF THE FERIMANITOL OVALBUMIN TABLET
TR201102142A1 (tr) Entekavi̇r veya farmasöti̇k olarak kabul edi̇lebi̇li̇r tuzlarini i̇çeren farmasöti̇k bi̇leşi̇m
TR201005911A2 (tr) Geliştirilmiş dissolüsyon profiline sahip bir ilaç formülasyonu.
PL404791A1 (pl) Stała doustna postać dawkowania zawierająca L-jabłczan sunitynibu i sposób jej wytwarzania